BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.

Otros idiomas Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Acciones

2315

CNE100005D27

Precio de cierre Hong Kong S.E. Otros sitios de cotización 00:00:00 16/05/2024			Varia. Cinco días.	Varia. 1 de enero.
9,2 ^CNY	-3,77 %		-9,98 %	-23,21 %

06/05	Biocytogen firma con Biocopy un acuerdo de evaluación y posible licencia de anticuerpos TCR-mímicos	CI
26/04	Las pérdidas de Biocytogen Pharmaceuticals se reducen en 2023	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Biocytogen Enters into Evaluation and Potential Licensing Agreement with Biocopy for TCR-mimic Antibodies	06/05
Biocytogen Pharmaceuticals' Loss Narrows in 2023	26/04
Biocytogen Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates	26/03
Biocytogen Pharmaceuticals Co., Ltd. Enters Collaboration with ABL Bio Inc. to Develop New Bispecific Antibody-Drug Conjugates	25/03
Biocytogen Pharmaceuticals Co., Ltd Announces Antibody Evaluation and Option Agreement with Gilead Sciences, Inc	19/02
Biocytogen Launches RenBiologics, a Sub-Brand Focused on Out-Licensing Fully Human Antibodies for Therapeutic Development	24/01
Biocytogen Pharmaceuticals Co., Ltd. Announces Launch of New Sub-Brand, RenBiologics	23/01
Biocytogen Enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma	09/01
Biocytogen Pharmaceuticals Gets License for Radiance Biopharma's Tumor Drug	08/01
Biocytogen Pharmaceuticals Co., Ltd. Enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma	08/01
Biocytogen and CtM Bio Achieve Milestone Progress in Co-Developing a TCR-mimic Antibody-based Multi-Specific T Cell Engager Targeting WT1/HLA-A02	28/12
Biocytogen Pharmaceuticals Co., Ltd. and CtM Biotech Co., Ltd Achieve Milestone Progress in Co-Developing A TCR-Mimic Antibody-Based Multi-Specific T Cell Engager Targeting WT1/HLA-A02	27/12
Biocytogen Enters into Multi-Target Antibody Agreement with Neurocrine Biosciences	20/12
Biocytogen Strikes Multi-Target Antibody Deal With Neurocrine Biosciences	20/12
Biocytogen Pharmaceuticals Co., Ltd. Enters into Multi-Target Antibody Agreement with Neurocrine Biosciences	20/12
Biocytogen Pharmaceuticals (Beijing) signs antibody evaluation, option and license agreement with Ona Therapeutics	19/12
Biocytogen, Ona Therapeutics Sign Agreement for Development of Antibody-Drug Conjugates	18/12
Biocytogen Pharmaceuticals Co., Ltd. Announce an Antibody Evaluation, Option and License Agreement with Ona Therapeutics	18/12
Biocytogen Pharmaceuticals Co., Ltd. Approves Election of Ms. Li Yan as A Non-Employee Representatives Supervisor of the Company	12/12

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Acciones

2315

CNE100005D27

Otros idiomas

Filtros